C12N 2310/3183
Diol linkers
Official title: Diol linkers, e.g. glycols or propanediols
C12N2310/3183 (Diol linkers) appears on 110 US grants and 169 published applications in this corpus.
Search patents in C12N- Granted patents
- 110
- Published applications
- 169
- Assignees
- 96
- Inventors
- 317
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 4 | 0 |
| 1998 | 0 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 4 | 1 |
| 2002 | 4 | 2 |
| 2003 | 2 | 8 |
| 2004 | 3 | 6 |
| 2005 | 0 | 7 |
| 2006 | 3 | 7 |
| 2007 | 1 | 5 |
| 2008 | 2 | 6 |
| 2009 | 3 | 4 |
| 2010 | 4 | 3 |
| 2011 | 6 | 8 |
| 2012 | 6 | 3 |
| 2013 | 3 | 6 |
| 2014 | 3 | 4 |
| 2015 | 6 | 2 |
| 2016 | 2 | 4 |
| 2017 | 7 | 6 |
| 2018 | 0 | 8 |
| 2019 | 5 | 9 |
| 2020 | 6 | 4 |
| 2021 | 4 | 13 |
| 2022 | 5 | 9 |
| 2023 | 2 | 15 |
| 2024 | 4 | 9 |
| 2025 | 7 | 14 |
| 2026 | 8 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Endosomal cleavable linkers15 Sep 2026US 12,735,702 B2Alnylam Pharmaceuticals, Inc.
- Human chromosome 9 open reading frame 72 (C9ORF72) iRNA agent compositions and methods of use thereof16 Jun 2026US 12,655,430 B2Alnylam Pharmaceuticals, Inc.
- Shingles vaccines comprising a TLR9 agonist10 Mar 2026US 12,569,553 B2Dynavax Technologies Corporation
- ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof3 Mar 2026US 12,565,653 B2Alnylam Pharmaceuticals, Inc.
- Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression17 Feb 2026US 12,553,050 B2Takeda Pharmaceutical Company Limited
- Methods and compositions for treating ctnnb1-associated disorders6 Aug 2026US 2026/0226466 A1Alnylam Pharmaceuticals, Inc.
- Stem-loop compositions and methods for inhibiting vascular endothelial growth factor6 Aug 2026US 2026/0226476 A1Albert Einstein College of Medicine
- Modified guide rna for reducing off-target editing30 Jul 2026US 2026/0218173 A1Integrated Dna Technologies, Inc.
- Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression30 Jul 2026US 2026/0218195 A1Takeda Pharmaceutical Company Limited
- Novel fas rnai therapeutics and uses thereof30 Jul 2026US 2026/0218198 A1Eli Lilly and Company
Most cited
By later US patents
- Methods of making single-stranded circular oligonucleotides178US 5,426,180 AResearch Corporation Technologies, Inc. · 1995
- Interfering RNA molecules134US 7,452,987 B2Silence Therapeutics GmbH · 2008
- Compositions and methods for inhibiting expression of anti-apoptotic genes115US 7,423,142 B2Alnylam Pharmaceuticals, Inc. · 2008
- Interfering RNA molecules77US 9,222,092 B2Silence Therapeutics GmbH · 2015
- Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines66US 5,693,773 AHybridon, Inc. · 1997